Tag Archive for: Chief Medical Officer

TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001

Elisabeth Svanberg, MD, PhD, appointed Chief Medical Officer, adding extensive global clinical–development and regulatory expertise Thomas Hanke, PhD, joins the Board, bringing more than 30 years of immunology, drug–discovery, and R&D experience Appointments strengthen TECregen as it advances TEC001 toward clinical development Basel, Switzerland, November 10, 2026 – TECregen, a biotechnology company pioneering thymus regeneration […]

Ona Therapeutics advances as a clinical-stage company and appoints Aleix Prat, MD, PhD, as Chief Medical Officer

More than half of the patients planned for the clinical study have already been enrolled, with the trial progressing rapidly through dose escalation Advancement of ONA-255 marks an important milestone following Ona’s $86.6 million Series B financing Internationally recognized oncologist and physician-scientist Aleix Prat, MD, PhD, appointed Chief Medical Officer, as Jutta Amersdorffer, MD, MBA, […]

Scenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officer

Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose […]

FundaMental Pharma appoints depression drug developer Dr. Hans Eriksson as Chief Medical Officer to advance its lead treatment-resistant depression candidate

Exceptional track record across multiple clinical development programs for depression, three of which have resulted in regulatory approvals Appointment strengthens confidence in clinical readiness and execution as the Company progresses toward first-in-human development Heidelberg, Germany – 2 June 2026 – FundaMental Pharma GmbH (or “the Company”), a preclinical-stage biopharmaceutical company focused on developing innovative, dual-acting N-methyl-D-aspartate […]

Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative ‘personalized off-the-shelf’ immunotherapy toward clinical development

Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s lead asset AT-108 into Phase 1 clinical development AT-108 is a transformative immunotherapy that triggers a personalized immune response against a patient’s tumors, despite being an off-the-shelf drug Asgard is currently progressing IND-enabling studies of this first-in-class therapy, which reprograms cancer cells in vivo, […]

© Optimum Strategic Communications.